Houston, TX29 Active Studies

Pulmonary Hypertension Clinical Trials in Houston, TX

Find 29 actively recruiting pulmonary hypertension clinical trials in Houston, TX. Connect with local research sites and explore new treatment options.

29
Active Trials
22
Sponsors
4,141
Enrolling

Recruiting Pulmonary Hypertension Studies in Houston

RecruitingHouston, TXNCT06072131

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for...

504 participants
Acrotech Biopharma Inc.
View Study Details
RecruitingHouston, TXNCT04077723

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin...

498 participants
Hoffmann-La Roche
View Study Details
RecruitingHouston, TXNCT04560673

Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy

This phase II trial investigates how well duloxetine and neurofeedback training work in treating patients with chemotherapy induced peripheral neuropathy. Duloxetine is a type of serotonin and norepin...

380 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TXNCT04994717

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free s...

284 participants
Amgen
View Study Details
RecruitingHouston, TXNCT04521231

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...

281 participants
Amgen
View Study Details
RecruitingHouston, TXNCT05948943

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as ...

232 participants
Novartis Pharmaceuticals
View Study Details
RecruitingHouston, TXNCT06435286

Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States

In a previous clinical trial in China and the United States (US), the investigators developed and validated a mobile, high-resolution microendoscope (mHRME) for screening and surveillance of esophagea...

200 participants
Baylor College of Medicine
View Study Details
RecruitingHouston, TXNCT06542250

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

174 participants
AstraZeneca
View Study Details
RecruitingHouston, TXNCT05416307

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of th...

156 participants
Electra Therapeutics Inc.
View Study Details
RecruitingHouston, TXNCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

142 participants
AstraZeneca
View Study Details
RecruitingHouston, TXNCT06469944

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingHouston, TXNCT06514794

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a ther...

125 participants
Wugen, Inc.
View Study Details
RecruitingHouston, TXNCT06137144

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

110 participants
AstraZeneca
View Study Details
RecruitingHouston, TXNCT05910801

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that ha...

100 participants
Academic and Community Cancer Research United
View Study Details
RecruitingHouston, TXNCT04039464

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosen...

100 participants
Johns Hopkins University
View Study Details
RecruitingHouston, TXNCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...

90 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingHouston, TXNCT03319901

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax...

82 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingHouston, TXNCT05563766

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a...

78 participants
VA Office of Research and Development
View Study Details
RecruitingHouston, TXNCT04496349

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL....

78 participants
Ascentage Pharma Group Inc.
View Study Details
RecruitingHouston, TXNCT06848231

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multip...

75 participants
Yoda Therapeutics Inc.
View Study Details
RecruitingHouston, TXNCT05475925

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

69 participants
Dren Bio
View Study Details
RecruitingHouston, TXNCT03698552

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibod...

57 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TXNCT06123338

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer....

49 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingHouston, TXNCT06522386

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with ...

40 participants
M.D. Anderson Cancer Center
View Study Details
RecruitingHouston, TXNCT05836259

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...

30 participants
Tenaya Therapeutics
View Study Details
RecruitingHouston, TXNCT07157787

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein cr...

30 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingHouston, TXNCT06797518

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. T...

20 participants
Novartis Pharmaceuticals
View Study Details
RecruitingHouston, TXNCT06730126

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called l...

15 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingHouston, TXNCT06983158

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether...

12 participants
Capsida Biotherapeutics, Inc.
View Study Details

About Pulmonary Hypertension Clinical Trials in Houston

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 29 pulmonary hypertension clinical trials recruiting participants in Houston, TX. These studies are seeking a combined 4,141 participants. Research is being sponsored by Acrotech Biopharma Inc., Hoffmann-La Roche, M.D. Anderson Cancer Center and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Houston — FAQ

Are there pulmonary hypertension clinical trials in Houston?

Yes, there are 29 pulmonary hypertension clinical trials currently recruiting in Houston, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 29 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov